Obesity Treatment Firm Kailera Upsizes IPO to Raise $625 Million

Kailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized initial public offering, marking the sector’s biggest US listing since 2021.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top